With the addition of Amgen (AMGN) and GSK (GSK), a total of 54 prescription drugs from six pharma companies will be available on the site.

TrumpRx launched last month with Eli Lilly (LLY), Pfizer (PFE), Novo Nordisk (NVO), and AstraZeneca (AZN) agreeing to sell their products on the site for cash-paying customers as part of President Donald Trump’s Most Favored Nation (MFN) drug pricing policy.

“GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favored-nations pricing marks another milestone for President Trump’s affordability push,” said White House spokesman Kush Desai.

On TrumpRx, Amgen (AMGN) plans to offer Amjevita, an off-patent version of AbbVie’s (ABBV) arthritis therapy Humira, at $299 compared to its current U.S. list price of $1,484.

The California-based pharma giant will also offer a roughly 60% discount for its migraine therapy, Aimovig, and the cholesterol drug Repatha on the website.

Meanwhile, Incruse, a treatment from GSK (GSK) for chronic obstructive pulmonary disease, will be on sale at $159 with a 55% discount. The British drugmaker’s other prescription medicines, Arnuity, Relenza, and Anoro, will be available at discounts ranging from 10% to 51% on TrumpRx, according to the report.

The post Amgen and GSK said to be adding products on TrumpRx appeared first on Up2info.com.

Citing topline data, UCB (UCBJF) stated that its BE BOLD trial achieved the primary endpoint related to a clinical measure called ACR50, which measures a 50% or greater improvement in American College of Rheumatology response criteria.

Bimzelx indicated superiority compared to Skyrizi in terms of ACR50 with a statistically significant effect over 16 weeks, the company added.

BE BOLD, which enrolled more than 500 adults with active psoriatic arthritis, indicated a well-tolerated safety profile for Bimzelx with no new safety signals, according to UCB (UCBJY).

The parallel group study is the fourth head-to-head study that showed Bimzelx’s superiority in psoriatic disease and the first in PsA.

The post AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis appeared first on Up2info.com.

The post AbbVie sees promising early-stage data for weight loss asset ABBV-295 appeared first on Up2info.com.

• The U.S. Food and Drug Administration is reportedly easing some requirements for drugmakers developing copycat versions of costly biologic medications in a bid to bring more competition to the market and lower costs.
• The agency plans to reduce the need for some studies that demonstrate the drugs, called biosimilars, are equivalent to the brand-name medications they’re modeled on, according to an FDA official and a document reviewed by Bloomberg News.
• The agency estimates the change could shave $20 million from the cost of developing a new biosimilar drug. The FDA is expected to issue draft guidance as ​soon as Monday.

The post FDA plans to relax testing rules to encourage biosimilar drugs: report appeared first on Up2info.com.

Prasad will depart as the director of the FDA’s Center for Biologics Evaluation and Research (CBER) at the end of next month, Makary said in an X post on Friday.

A professor in the epidemiology and biostatistics department at the University of California, Prasad joined the FDA in May 2025 after the former CBER head, Peter Marks, abruptly resigned from the position. He was later given the additional role of the FDA’s chief medical and scientific officer in June.

Prasad suddenly left the agency in late July in the aftermath of the FDA response to the several deaths linked to Elevidys, a treatment for Duchenne muscular dystrophy developed by Sarepta Therapeutics (SRPT) and Bayer (BAYRZF).

After rejoining the FDA in August to assume his original position as the director of CBER, Prasad oversaw several controversial decisions at CBER, most recently the FDA’s handling of an experimental therapy developed by uniQure (QURE) targeting a rare disorder called Huntington’s disease.

“Under his leadership, his center hit a record number of approvals in Dec.,” Makary wrote in an X post last night, adding, “He got a tremendous amount accomplished within his one-year sabbatical from UCSF and will be returning back to his academic home later next month.”

The FDA will name Prasad’s successor before his departure, Makary said.

The post FDA vaccine chief to leave the agency again appeared first on Up2info.com.

The post AbbVie sees positive late-stage results for subcutaneous Skyrizi in Crohn’s appeared first on Up2info.com.

For the week, Nasdaq (COMP:IND) rose 1%, while Dow (DJI) gained 1.4%, respectively. Wall Street had a

The post Notable analyst calls this week: Alphabet, Comcast and IBM among top picks appeared first on Up2info.com.

The bank has a $260 price target (~14% upside based on Feb. 24 close).

Analyst Trung Huynh said that others have been wrong about AbbVie in claiming that “the ‘beat-and-raise’ story is over and competition threatens immunology.”

He noted that sales of Skyrizi and Rinvoq are poised to increase given the company is still in “early indication expansion” for the drugs.

Huynh added that AbbVie benefits from no near-term loss of exclusivity issues for its currently marketed medicines and doesn’t need to engage in M&A.

“At <16x, ABBV trades closer to Pharma’s facing large LOEs (MRK) than high growth companies (LLY) when it delivers top-tier c.17% EPS growth (peers 6%)—PEG valuation is more attractive than LLY,” he wrote.

Huynh said that in 2026, Rinvoq has three catalysts, and Skyrizi has two. The FDA is also expected to render a decision on tavapadon for Parkinson’s disease, while AbbVie is slated to release phase 1 data for long-acting amylin analogue ABBV-295 for obesity, and lutikizumab phase 3 data in hidradenitis suppurativa.

The post AbbVie a new outperform at RBC Capital Markets on durable growth appeared first on Up2info.com.

The post AbbVie earmarks $380M to build two manufacturing facilities in Illinois appeared first on Up2info.com.

The approval is supported by data from the Phase 3 AMPLIFY trial.

This milestone updates the treatment of CLL in the first-line setting, establishing the Venclexta and acalabrutinib combination as the first and only all-oral, fixed-duration regimen for previously untreated patients, the company said.

The regimen supports current standards of care by offering patients the potential for time off treatment and giving providers a new, targeted option that combines two classes of oral medications for CLL.

“This FDA approval marks a significant milestone for AbbVie and, more importantly, for people living with CLL,” said Svetlana Kobina, vice president, global medical affairs, oncology, AbbVie.

“As the first and only all-oral, fixed-duration combination regimen for previously untreated patients, the Venclexta plus acalabrutinib approval expands choice and flexibility for patients and providers navigating complex treatment decisions in CLL.”

The post AbbVie wins FDA approval for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia appeared first on Up2info.com.